Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$4065.00
+35.00 (+0.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $7.0B · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$50.2B
P/E
2.2x
↓EV/EBITDA
3.8x
↓ROE
13.9%
↑Gross Margin
64.8%
↑Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.5%
FCF CAGR
—
FCF margin
-1.8%
FCF / Net income
-0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $120.69B · net income $22.29B · FCF $-2.21B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $120.69B | $120.69B | $113.33B | $93.71B | $76.26B |
| Net Income | $22.29B | $22.29B | $29.69B | $12.34B | $12.31B |
| EBITDA | $32.80B | $32.80B | $40.93B | $16.21B | $18.11B |
| EPS | 1808.00 | 1808.00 | 2383.00 | 1087.00 | 986.00 |
| Gross Margin | 64.8% | 64.8% | 61.7% | 60.9% | 59.9% |
| Operating Margin | 2.1% | 2.1% | 10.3% | 9.3% | 14.6% |
| Net Margin | 18.5% | 18.5% | 26.2% | 13.2% | 16.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.66 | 0.09 | 0.13 |
| Current Ratio | 0.52 | 0.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.21B | $-2.21B | $11.85B | $7.00B | $2.81B |
| Returns | |||||
| ROE | 13.9% | 13.9% | 24.8% | 13.9% | 15.9% |
| Valuation | |||||
| P/E | 2.25 | 2.25 | 2.56 | 5.78 | 6.51 |
| EV/EBITDA | 3.80 | 3.80 | 3.76 | 4.57 | 4.96 |
| P/B | 0.31 | 0.31 | 0.63 | 0.80 | 1.03 |
| Growth & Yield | |||||
| Revenue Growth | 6.5% | 6.5% | 20.9% | 22.9% | — |
| EPS Growth | -24.1% | -24.1% | 119.2% | 10.2% | — |
| Dividend Yield | 3.7% | 3.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-41.6%
EPS terminal req.
$360.70
Spread vs growth
17.4%
5Y implied EPS CAGR
-24.7%
EPS terminal req.
$436.45
Spread vs growth
0.6%
10Y implied EPS CAGR
-9.0%
EPS terminal req.
$702.90
Spread vs growth
-15.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.5%
Start / end P/E
2.7x → 2.2x
EPS bridge
2383.00 → 1808.00
Residual
+3.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.